The Complement Pharma LNA Program has developed compounds which use antisense principles. These compounds are based on Locked-nucleic-acid (LNA) technology and target complement C6, which is mainly synthesized in the liver. These compounds enhance recovery in a mouse model with acute neurodegeneration, a "nerve crush" assay and reduce disease progression in the ADEAE mouse: a model of severe nerve demyelination seen in patients with Multiple Sclerosis (MS).